Performance of the ASAS Health Index for the Evaluation of Spondyloarthritis in Daily Practice.


Journal

The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984

Informations de publication

Date de publication:
01 10 2020
Historique:
accepted: 13 04 2020
pubmed: 3 5 2020
medline: 1 9 2021
entrez: 3 5 2020
Statut: ppublish

Résumé

The Assessment of SpondyloArthritis international Society Health Index (ASAS HI) is a tool designed to assess disease impact in spondyloarthritis (SpA), but its clinical performance is barely known. We aimed to test the clinimetric properties of ASAS HI in a real clinical setting. This cross-sectional study included 111 consecutive patients with SpA. The measurement properties of ASAS HI were tested against conventional assessment measures. Convergent validity was assessed by Spearman rho correlations, while discriminative validity was analyzed through receiver-operating characteristic (ROC) curves. A multivariate regression analysis was designed to identify ASAS HI items associated with active disease. The average ASAS HI was 5.4 ± 3.8 (interquartile range 3-8). ASAS HI showed high convergent validity against other SpA measures (rho ≥ 0.70, p < 0.0005). The optimal criteria for detecting high/very high disease activity Ankylosing Spondylitis Disease Activity Score (ASDAS) categories was an ASAS HI score > 6, area under the ROC curve 0.86 (95% CI 0.78-0.92), positive likelihood ratio 7.3 (95% CI 3.1-17.1), p < 0.0001. The ASAS HI items significantly associated with Bath Ankylosing Spondylitis Disease Activity Index active disease were "I often get frustrated" (OR 9.2, 95% CI 1.2-69.4, p = 0.032), and "I sleep badly at night" (OR 7.7, 95% CI 1.4-41.6, p = 0.018). As for ASDAS, it was "pain sometimes disrupts my normal activities" (OR 8.7, 95% CI 1.7-45.2, p = 0.010). The ASAS HI is a useful and simple instrument for its application in daily practice. Given its good clinimetric properties, it could be used as an additional instrument to evaluate SpA.

Identifiants

pubmed: 32358161
pii: jrheum.200025
doi: 10.3899/jrheum.200025
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1483-1489

Commentaires et corrections

Type : CommentIn

Auteurs

Sara Alonso-Castro (S)

S. Alonso-Castro, MD, E. Pardo, MD, L. Charca, MD, M. Pino, MD, S. Fernández, MD, M. Alperi, MD, L. Arboleya, MD, R. Queiro, MD, PhD, Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.

Estefanía Pardo (E)

S. Alonso-Castro, MD, E. Pardo, MD, L. Charca, MD, M. Pino, MD, S. Fernández, MD, M. Alperi, MD, L. Arboleya, MD, R. Queiro, MD, PhD, Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.

Lilyan Charca (L)

S. Alonso-Castro, MD, E. Pardo, MD, L. Charca, MD, M. Pino, MD, S. Fernández, MD, M. Alperi, MD, L. Arboleya, MD, R. Queiro, MD, PhD, Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.

Marina Pino (M)

S. Alonso-Castro, MD, E. Pardo, MD, L. Charca, MD, M. Pino, MD, S. Fernández, MD, M. Alperi, MD, L. Arboleya, MD, R. Queiro, MD, PhD, Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.

Sabela Fernández (S)

S. Alonso-Castro, MD, E. Pardo, MD, L. Charca, MD, M. Pino, MD, S. Fernández, MD, M. Alperi, MD, L. Arboleya, MD, R. Queiro, MD, PhD, Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.

Mercedes Alperi (M)

S. Alonso-Castro, MD, E. Pardo, MD, L. Charca, MD, M. Pino, MD, S. Fernández, MD, M. Alperi, MD, L. Arboleya, MD, R. Queiro, MD, PhD, Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.

Luis Arboleya (L)

S. Alonso-Castro, MD, E. Pardo, MD, L. Charca, MD, M. Pino, MD, S. Fernández, MD, M. Alperi, MD, L. Arboleya, MD, R. Queiro, MD, PhD, Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.

Rubén Queiro (R)

S. Alonso-Castro, MD, E. Pardo, MD, L. Charca, MD, M. Pino, MD, S. Fernández, MD, M. Alperi, MD, L. Arboleya, MD, R. Queiro, MD, PhD, Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain. rubenque7@yahoo.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH